Although recent studies have shown that Notch and EGFR signaling are associated with drug resistance, antiangiogenic agent and EGFR tyrosine kinase inhibitors have been accepted for NSCLC treatment 30, 31. Here, EGFR is linked to non-small cell lung carcinoma.